Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pina M Cardarelli

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Plos One|September 10, 2016
Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque ToxicologyMark J Selby, John J Engelhardt, Robert J Johnston, et al.
Plos One|November 19, 2016
Correction: Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque ToxicologyMark J Selby, John J Engelhardt, Robert J Johnston, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 20, 2018
A Novel, Fully Human Anti-fucosyl-GM1 Antibody Demonstrates Potent <i>In Vitro</i> and <i>In Vivo</i> Antitumor Activity in Preclinical Models of Small Cell Lung CancerPaul Ponath, Daniel Menezes, Chin Pan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 30, 2009
In vitro and in vivo characterization of MDX-1401 for therapy of malignant lymphomaPina M Cardarelli, Maria-Cristina Moldovan-Loomis, Ben Preston, et al.
Nature Biotechnology|November 28, 2006
Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minorKevin M Cox, Jason D Sterling, Jeffrey T Regan, et al.
Analytical Chemistry|December 21, 2019
Universal Affinity Capture Liquid Chromatography-Mass Spectrometry Assay for Evaluation of Biotransformation of Site-Specific Antibody Drug Conjugates in Preclinical StudiesSrikanth Kotapati, David Passmore, Sayumi Yamazoe, et al.
Cancer Research|September 23, 2003
CD10 is a key enzyme involved in the activation of tumor-activated peptide prodrug CPI-0004Na and novel analogues: implications for the design of novel peptide prodrugs for the therapy of CD10+ tumorsChin Pan, Pina M Cardarelli, Matthew H Nieder, et al.
Oncotarget|December 10, 2015
Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathwayManoj K Kashyap, Deepak Kumar, Harrison Jones, et al.
Plos One|October 25, 2023
GPC-100, a novel CXCR4 antagonist, improves in vivo hematopoietic cell mobilization when combined with propranololDevki D Sukhtankar, Juan José Fung, Mi-Na Kim, et al.
ACS Medicinal Chemistry Letters|March 19, 2021
DNA-Model-Based Design and Execution of Some Fused Benzodiazepine Hybrid Payloads for Antibody-Drug Conjugate ModalityPrasanna Sivaprakasam, Ivar McDonald, Christiana Iwuagwu, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Plos One|September 10, 2016
Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque ToxicologyMark J Selby, John J Engelhardt, Robert J Johnston, et al.
Plos One|November 19, 2016
Correction: Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque ToxicologyMark J Selby, John J Engelhardt, Robert J Johnston, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 20, 2018
A Novel, Fully Human Anti-fucosyl-GM1 Antibody Demonstrates Potent <i>In Vitro</i> and <i>In Vivo</i> Antitumor Activity in Preclinical Models of Small Cell Lung CancerPaul Ponath, Daniel Menezes, Chin Pan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 30, 2009
In vitro and in vivo characterization of MDX-1401 for therapy of malignant lymphomaPina M Cardarelli, Maria-Cristina Moldovan-Loomis, Ben Preston, et al.
Nature Biotechnology|November 28, 2006
Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minorKevin M Cox, Jason D Sterling, Jeffrey T Regan, et al.
Analytical Chemistry|December 21, 2019
Universal Affinity Capture Liquid Chromatography-Mass Spectrometry Assay for Evaluation of Biotransformation of Site-Specific Antibody Drug Conjugates in Preclinical StudiesSrikanth Kotapati, David Passmore, Sayumi Yamazoe, et al.
Cancer Research|September 23, 2003
CD10 is a key enzyme involved in the activation of tumor-activated peptide prodrug CPI-0004Na and novel analogues: implications for the design of novel peptide prodrugs for the therapy of CD10+ tumorsChin Pan, Pina M Cardarelli, Matthew H Nieder, et al.
Oncotarget|December 10, 2015
Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathwayManoj K Kashyap, Deepak Kumar, Harrison Jones, et al.
Plos One|October 25, 2023
GPC-100, a novel CXCR4 antagonist, improves in vivo hematopoietic cell mobilization when combined with propranololDevki D Sukhtankar, Juan José Fung, Mi-Na Kim, et al.
ACS Medicinal Chemistry Letters|March 19, 2021
DNA-Model-Based Design and Execution of Some Fused Benzodiazepine Hybrid Payloads for Antibody-Drug Conjugate ModalityPrasanna Sivaprakasam, Ivar McDonald, Christiana Iwuagwu, et al.
Pageof 3